Semaphorin 3A在系统性红斑狼疮合并血小板减少患者中的水平及意义

doi:10.19723/j.issn.1671-167X.2020.05.016

摘要/Abstract

摘要：

目的:通过测定血清Semaphorin 3A(Sema3A)的水平,分析Sema3A与系统性红斑狼疮(systemic lupus erythematosus,SLE)血小板减少的相关性。方法: 应用酶联免疫吸附法检测170例SLE患者、50例干燥综合征(Sjögren’s syndrome,SS)患者、19例脾功能亢进(hypersplenism,HS)患者及150例健康对照(healthy controls,HC)血清中Sema3A的水平,收集患者及健康对照的临床资料及实验室检查,实验室检查主要为患者的血常规及骨髓穿刺活检结果。根据是否合并血小板减少及血小板减少是否缓解,将SLE患者分为SLE合并血小板减少组(41例)、SLE合并血小板减少缓解组(28例)及SLE未合并血小板减少组(101例)。根据是否合并血小板减少,将SS患者分为SS合并血小板减少组(18例)及SS未合并血小板减少组(32例)。将28例进行骨髓穿刺活检的SLE患者,根据骨髓象结果从骨髓增生情况方面将其分为骨髓增生正常组(19例)和增生减低组(9例),从巨核细胞成熟方面将其分为有巨核细胞成熟障碍组(8)和无巨核细胞成熟障碍组(20例)。比较各组Sema3A水平差异,并分析各组患者血清Sema3A水平与血小板的相关性及不同骨髓象间血清Sema3A的水平。结果: (1)SLE患者血清Sema3A水平较HC显著降低[(3.84±2.76) μg /L vs. (6.96±2.62) μg/L,P<0.001],SS患者血清Sema3A水平亦较HC显著降低[(4.35±3.57) μg/L vs. (6.96±2.62) μg/L,P<0.001],HS患者血清Sema3A水平较HC也明显降低[(5.67±2.26) μg/L vs. (6.96±2.62) μg/L,P=0.041]。(2)SLE患者血清Sema3A水平较SS患者降低,但差异无统计学意义[(3.84±2.76) μg/L vs. (4.35±3.57) μg/L,P=0.282],SLE患者血清Sema3A水平与HS患者相比显著降低,差异有统计学意义[(3.84±2.76) μg/L vs. (5.67±2.26) μg/L,P=0.006]。(3)SLE合并血小板减少组Sema3A水平显著低于SLE合并血小板减少缓解组[(1.28±1.06) μg/L vs. (3.83±2.65) μg/L,P<0.001]和SLE未合并血小板减少组[(1.28±1.06) μg/L vs. (4.87±2.60) μg/L,P<0.001],而SLE合并血小板减少缓解组与SLE未合并血小板减少组相比,差异无统计学意义[(3.83±2.65) μg/L vs. (4.87±2.60) μg/L,P=0.123]。SLE合并血小板减少组患者Sema3A水平与SS合并血小板减少组患者相比降低,但差异无统计学意义[(1.28±1.06) μg/L vs. (1.68±1.11) μg/L,P=0.189]。(4)相关性分析显示SLE患者的Sema3A水平与血小板显著相关(r=0.600,P<0.001), SS患者的Sema3A水平与血小板亦呈明显的正相关(r=0.573,P<0.001),但HS患者与Sema3A却没有表现出明显的相关性(P=0.393)。(5)血清Sema3A在骨髓增生正常和减低的SLE患者,及有和无巨核细胞成熟障碍的SLE患者中的水平差异无统计学意义(P>0.05)。结论:血清Sema3A在多种合并血小板减少的疾病中水平普遍下降,SLE患者血清Sema3A水平显著降低,并与血小板呈明显正相关,在SS患者中亦可得出类似结论,提示Sema3A与结缔组织病的血小板减少相关。

关键词: Semaphorin 3A, 红斑狼疮, 系统性, 血小板减少

Abstract:

Objective: To measure the level of serum Semaphorin 3A (Sema3A) and to analyze the relationship between serum Sema3A and systemic lupus erythematosus (SLE) with thrombocytopenia. Methods: The concentration of serum Sema3A was detected by enzyme-linked immuno sorbent assay (ELISA) in 170 SLE patients, 50 Sjögren’s syndrome (SS) patients, 19 hypersplenism (HS) patients and 150 healthy controls (HC). Based on the presence of thrombocytopenia and whether the thrombocytopenia was in remission, the SLE patients were divided into three groups: SLE with thrombocytopenia (41 cases), SLE with thrombocytopenia remission (28 cases), and SLE without thrombocytopenia (101 cases). According to whether there was thrombocytopenia, the SS patients were divided into SS with thrombocytopenia (18 cases) and SS without thrombocytopenia (32 cases). The 28 SLE patients who underwent bone marrow aspiration biopsy were divided into two groups from the aspect of whether the bone marrow hyperplasia was normal (19 cases) or low (9 cases), as well as from the aspect of whether the maturity disturbance of megakaryocyte was positive (8 cases) or negative (20 cases). The serum Sema3A levels in SLE, SS, HS with HC were compared, meanwhile, the correlation between serum Sema3A level and platelet (PLT) in the patients with different diseases analyzed. Results: (1) Serum Sema3A levels in SLE were significantly lower than in HC [(3.84±2.76) μg/L vs. (6.96±2.62) μg/L, P<0.001], serum Sema3A levels in SS were also obviously lower than in HC [(4.35±3.57) μg/L vs. (6.96±2.62) μg/L, P<0.001], and in HS it was lower than HC at a certain extant [(5.67±2.26) μg/L vs. (6.96±2.62) μg/L, P=0.041]. (2) Serum Sema3A levels in SLE were slightly lower than in SS, but there was no significant difference [(3.84±2.76) μg/L vs. (4.35±3.57) μg/L, P=0.282]. However, when compared with HS, serum Sema3A levels in SLE were significantly lower [(3.84±2.76) μg/L vs. (5.67±2.26) μg/L, P=0.006]. (3) Serum Sema3A concentration in SLE with thrombocytopenia was significantly lower than in SLE with thrombocytopenia remission [(1.28±1.06) μg/L vs. (3.83±2.65) μg/L, P<0.001], and in SLE patients without thrombocytopenia [(1.28±1.06) μg/L vs. (4.87±2.60) μg/L, P <0.001]. There was no significant difference between SLE with thrombocytopenia remission and SLE without thrombocytopenia [(3.83±2.65) μg/L vs. (4.87±2.600 μg/L, P=0.123]. Serum Sema3A concentration in SLE with thrombocytopenia was slightly lower than in SS with thrombocytopenia, but there was no significant difference [(1.28±1.06) μg/L vs. (1.68±1.11) μg/L, P=0.189]. (4) Strong positive correlations were found between serum Sema3A and PLT in SLE (r=0.600, P<0.001). Positive correlations were also found between serum Sema3A and PLT in SS (r=0.573, P<0.001). However, there was no such correlation showed in HS patients (P=0.393). (5) There was no significant difference of serum Sema3A concentration in SLE whether the bone marrow hyperplasia was normal or low. And the same situation appeared in the patients whether the maturity disturbance of megakaryocyte was positive or negative (P>0.05). Conclusion: Serum Sema3A was significantly reduced in SLE patients, and it was highly correlated with the blood damage. Similar conclusions could be drawn in patients with SS. The serum level of Sema3A was generally decreasing in desmosis which merged thrombocytopenia, and was obviously positive correlated with platelet counts.

Key words: Semaphorin 3A, Lupus erythematosus, systemic, Thrombocytopenia

中图分类号:

R593.24

郭倩, 马晓旭, 高辉, 石连杰, 钟昱超, 谢琳峰, 邵苗, 张学武. Semaphorin 3A在系统性红斑狼疮合并血小板减少患者中的水平及意义[J]. 北京大学学报（医学版）, 2020, 52(5): 892-896.

Qian GUO, Xiao-xu MA, Hui GAO, Lian-jie SHI, Yu-chao ZHONG, Lin-feng XIE, Miao SHAO, Xue-wu ZHANG. Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus[J]. Journal of Peking University (Health Sciences), 2020, 52(5): 892-896.

图/表 3

表1

图1

图2

参考文献 17

[1]	Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition[J]. Immunity, 2008,28(3):402-413. doi: 10.1016/j.immuni.2008.01.012
[2]	Ji JD, Park-Min KH, Ivashkiv LB. Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages[J]. Hum Immunol, 2009,70(4):211-217. doi: 10.1016/j.humimm.2009.01.026
[3]	Lepelletier Y, Moura IC, Hadj-Slimane R, et al. Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization[J]. Eur J Immunol, 2006,36(7):1782-1793. doi: 10.1002/eji.200535601 pmid: 16791896
[4]	Catalano A, Caprari P, Moretti S, et al. Semaphorin 3A is expressed by tumor cells and alters T-cell signal transduction and function[J]. Blood, 2006,107(8):3321-3329. doi: 10.1182/blood-2005-06-2445 pmid: 16380453
[5]	Vadasz Z, Haj T, Halasz K, et al. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus[J]. Arthritis Res Ther, 2012,14(3):R146. doi: 10.1186/ar3881 pmid: 22697500
[6]	Sturrock RD. Hematologic disorders in rheumatic disease[J]. Curr Opin Rheumatol, 1991,3(1):172. doi: 10.1097/00002281-199102000-00024 pmid: 2043444
[7]	Kashiwagi H, Shiraga M, Kato H, et al. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A[J]. Blood, 2005,106(3):913-921. doi: 10.1182/blood-2004-10-4092 pmid: 15831706
[8]	高辉, 马晓旭, 郭倩, 等. Sema3A在系统性红斑狼疮患者血清及单个核细胞中的表达[J]. 中华医学杂志, 2017,97(5):370-374.
[9]	Okuno T, Nakatsuji Y, Kumanogoh A. The role of immune semaphorins in multiple sclerosis[J]. FEBS Lett, 2011,585(23):3829-3835. doi: 10.1016/j.febslet.2011.03.033
[10]	Eixarch H, Gutierrez-Franco A, Montalban X, et al. Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis[J]. Trends Mol Med, 2013,19(3):157-164. doi: 10.1016/j.molmed.2013.01.003 pmid: 23419749
[11]	Takagawa S, Nakamura F, Kumagai K, et al. Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis[J]. BMC Musculoskelet Disord, 2013,14:40. doi: 10.1186/1471-2474-14-40 pmid: 23343469
[12]	Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein Ⅱb/Ⅲa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura[J]. Blood, 2003,101(2):621-623. doi: 10.1182/blood-2002-07-2157 pmid: 12393517
[13]	Shenoy S, Mohanakumar T, Chatila T, et al. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias[J]. Clin Immunol, 2001,99(2):266-275. doi: 10.1006/clim.2001.5017
[14]	Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chro-nic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response[J]. Blood, 2004,103(7):2645-2647. doi: 10.1182/blood-2003-07-2268 pmid: 14670926
[15]	Ling Y, Cao X, Yu Z, et al. Circulating dendritic cells subsets and CD4⁺Foxp3⁺ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome [J]. Eur J Haematol, 2007,79(4):310-316. doi: 10.1111/j.1600-0609.2007.00917.x pmid: 17692100
[16]	Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J]. Nat Med, 2003,9(9):1123-1124. doi: 10.1038/nm921 pmid: 12937414
[17]	Wannemacher KM, Wang L, Zhu L, et al. The role of sema-phorins and their receptors in platelets: Lessons learned from neuronal and immune synapses[J]. Platelets, 2011,22(6):461-465. doi: 10.3109/09537104.2011.561891

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Groups	n	Age/years	Male/Female, n	PLT/(×10⁹/L)	Sema3A/(μg/L)	P^*
SLE	170	34.49±14.53	22/148	163.88±88.61	3.84±2.76	<0.001
SS	50	51.63±13.13	6/44	125.84±74.90	4.35±3.57	<0.001
HS	19	57.58±11.16	11/8	51.0(11.0-116.0)	5.67±2.26	0.041
HC	150	42.05±12.82	31/119		6.96±2.62